Adenoid Cystic Carcinoma

Breast AdCC, though rare, requires heightened clinical awareness for accurate diagnosis and management. This case underscores the potential role of genetic evaluation in rare breast cancer subtypes and the importance of continued case reporting to guide future recommendations.

However, differences in TIL rate and CD45RO expression indicate that each of the SGT tumor types may have distinguished immune microenvironments. Malignant SGTs have higher infiltration of activated immune cells, and, thereby, these cells can be considered as good indicators of patient's status.

Despite sharing a chromosomal translocation partner (the EWSR1 gene) with sarcomas, MECA are most related to other salivary carcinomas. Further exploration of IGF1R as a therapeutic target in MECA is warranted. We also make available the 27 patients' next generation DNA exome and RNA sequencing through the EGA Repository.

Tumor emboli were cytokeratin positive, supporting epithelial origin and an IMC diagnosis, and neoplastic cells were immunopositive for cytokeratin with concurrent vimentin immunoreactivity. This case highlights the clinicopathologic basis of IMC and the diagnostic importance of including full-thickness skin and adjacent subcutis in the sampling plan.

Despite presenting with locally advanced pT4a disease and early pulmonary metastasis, the patient achieved 5-year local control following total laryngectomy and adjuvant radiotherapy. The findings suggest that molecular profiling can identify non-MYB-driven subtypes and guide individualized management for atypical laryngeal malignancies.

These show different patterns and variants, and have different nomenclature depending on the histological diversity/embryological development of the organ in which they are localized. We also noticed that adenoid cystic carcinoma and basaloid carcinoma have similar histology and are transitional to each other in many organs, necessitating a common nomenclature.

P2, N=28, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Feb 2026 --> Dec 2026

Fluorescence in situ hybridization-based detection of 6q-loss and 14q-loss by probe ESR1-6q25 and FOS-14q24 provided a rapid and clinically feasible validation in ACC prognostic assessment. Further multicohort and multifactor analysis demonstrated the robustness and independence of the prognostic value in overall survival and metastasis-free survival of the molecular classification method.

Isolated liver metastasis as the initial manifestation of ACC is exceedingly uncommon. Histopathology and immunohistochemistry are essential for diagnosis. Long-term follow-up is crucial due to the risk of delayed distant metastasis and the lack of standardized management guidelines.

At 12-month follow-up, local recurrence and bilateral axillary metastases were identified. This case emphasizes the diagnostic challenge of SB-AdCC, its overlap with basaloid carcinoma, and the importance of recognizing its distinct morphological and molecular features.

Functionally, these exosome-educated CAFs promoted the epithelial-mesenchymal transition in ACC cells and facilitated lung metastasis in vivo via an IL-17-dependent signaling axis. Overall, these findings establish exosomal S100A9 as a crucial mediator of TME reprogramming, suggesting that targeting the S100A9-IL-17 axis may serve as a promising therapeutic strategy for disrupting ACC lung metastasis.

While the primary end point of best ORR was not met in this nonrandomized clinical trial, amivantamab was well tolerated, and most patients exhibited disease stabilization. ClinicalTrials.gov Identifier: NCT05074940.